Dylan Miller

Dylan Miller is an associate in Goodwin’s Business Law department and a member of the firm’s Life Sciences practice. His practice focuses on mergers and acquisitions and other strategic corporate matters for public and private companies, venture-backed companies, private equity sponsors, and other investors. He advises clients on a range of transactions, including leveraged buyouts, carve-out and asset acquisitions, joint ventures, venture capital and growth equity financings, royalty financings, and licensing and collaboration arrangements.

Dylan works primarily with companies operating across the life sciences, healthcare, and technology sectors. His experience includes representing biotechnology, diagnostics, medical device, digital health, pharmacy, and other healthcare services companies — as well as their investors — in acquisitions, strategic investments, and other complex business combinations, including transactions involving management services organization (MSO) structures. He also advises private equity sponsors and their portfolio companies in connection with acquisitions, leveraged buyouts, and related transactions.

In addition, Dylan counsels emerging growth companies and their investors on corporate governance, investor rights arrangements, and other general corporate matters throughout the company lifecycle. He regularly works with founders, management teams, and boards of directors as companies scale and pursue strategic growth initiatives.

Some of Dylan’s representative matters include:

• Represented Halda Therapeutics in its $3.05 billion sale to Johnson & Johnson.
• Represented Fresenius Medical Care in the sale of its outpatient cardiovascular clinics business to United Healthcare Group.
• Represented a publicly traded biopharmaceutical company in its acquisition of a clinical-stage small-molecule therapeutics company.
• Represented a publicly traded diagnostics company in its acquisition of a point-of-care diagnostics company.
• Represented a leading life sciences growth equity fund in its lead investment in a surgical device company.
• Represented Kingswood Capital Management in its acquisition of Infortree Global Solutions.
• Represented Fortress Investment Group in its acquisition of Gypsum Technologies (Gyptech).
• Represented Arlington Capital Partners in its acquisition of TEAM Technologies.
• Represented Guardian Capital Partners in its acquisition of Nwestco.
• Represented Repisodic in its sale to Trella Health.
• Represented Cornerstone Specialty Network in connection with its capital investment by Provider Network Holdings, a portfolio company of Waud Capital Partners.
• Represented Chardan in connection with ZOOZ Power Ltd.’s $159 million private placement and $1 billion at-the-market program.
• Represented Lead Edge Capital Management in its lead investment in a continuation fund supporting Comply365 Holdings.
• Represented a national provider of fire protection and electronic security services in connection with multiple strategic acquisitions.
• Represented a national network of veterinary practices in connection with multiple strategic partnerships with veterinary hospitals and clinics.